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Molecular Modelling Studies of Bovine and Camel Chymosin-k-Casein
Complexes
Jesper Sørensen1, David S. Palmer1, Anders U. Christensen1, Leyla Celik2,
Karsten B. Qvist3, Birgit H. Schiøtt1.
1Aarhus University, Aarhus C, Denmark, 2Yale University, New Haven, CT,
USA, 3Chr. Hansen, Hørsholm, Denmark.
We present computational studies of two homologous mammalian aspartic pro-
teases (calf and camel chymosin) complexed with 16-residue fragments of their
native peptide ligands (cow and camel k-casein) and the cross-complexes. Us-
ing molecular docking calculations, homology modelling and molecular dy-
namics simulations, we compare the binding modes of the four systems. The
complexes are of industrial interest because camel chymosin has recently
been marketed as an alternative to
bovine chymosin as an enzyme to
clot milk in cheese manufacturing.
The camel enzyme has been shown
to have 70% higher clotting activity
and only 20% of the unspecific prote-
ase activity for bovine k-casein as
compared to the bovine enzyme. In-
terestingly, bovine chymosin has
a very low proteolytic rate for camel
k-casein. The models provide puta-
tive atomic coordinates for these
complexes, for which there are no
available crystallographic or NMR
structures, and help to explain some
existing experimental results.
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Changes in HIV-1 Protease-Inhibitor Interaction Due to Amino Acids
Polymorphisms and Drug-Pressure Selected Mutations
Angelo M. Veloro, Mandy E. Blackburn, Jamie L. Kear, Xi Huang,
Gail E. Fanucci.
University of Florida, Gainesville, FL, USA.
Both pulsed electron paramagnetic resonance (EPR) and 2D HSQC NMR are
used to study HIV-1 protease-inhibitor binding by monitoring the changes in
flaps conformation and amide chemical shifts. For all NMR and EPR experi-
ments, here, we used an inactive (D25N) enzyme construct and nine FDA
approved inhibitors. Results show that several inhibitors induce a closed flap
conformation and cause significant splitting of the amide backbone chemical
shifts due to a removal of the homodimer symmetry upon binding. Other inhib-
itors are found to interact more weakly with the protein, resulting in incomplete
flap closures and perturbation of HSQC peaks due to chemical exchange. Qual-
itatively, both the pulsed EPR and NMR methods can discern different degrees
of protease-inhibitor interactions, which we define as strong, moderate, and
weak. The stability of each of the protease-inhibitor formed was determined
by measuring the transition midpoint (Tm) with differential scanning calorim-
etry (DSC). Inhibitors classified as ‘‘strong binders’’ have higher Tm values. To
determine changes in protease-inhibitor interaction with drug resistant con-
structs, we used the inactive sub-Saharan HIV-1 protease (8 amino acid poly-
morphisms), MDR769 (11 mutations) and V6 (8 mutations). Our pulsed EPR
and NMR results show differences in inhibitor interactions in subtype C,
MDR769 and V6 compared to subtype B.
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The process of ubiquitylation involves the transfer of the small 76-residue pro-
tein ubiquitin (Ub) between a series of enzymes (E1, E2, E3) until it binds to
a lysine residue of the substrate protein. When repeated several times, the
E1-E2-E3 cascade forms a K48-linked polyubiquitin (poly-Ub) chain targeting
the protein substrate for 26S proteasomal degradation. The E2 enzyme is the
key protein in this cascade as it must recognize both the E1 and E3 enzymes,
label the substrate, as well as form a covalent thiolester with Ub. Cdc34 is
a class II E2 conjugating enzyme in the Ub-dependent degradation pathway
of cell cycle proteins. It is comprised of a ~170 residue catalytic domain, com-
mon to all E2 enzymes, which contains the active site cysteine (C93). Two
unique features of cdc34 are its acidic loop (residues 102-113) and acidic tail
(residues 171-236), both of which are required to produce poly-Ub chains.
However, the underlying mechanism that these regions have on chain assemblyremains unclear. We have used NMR spectroscopy to study protein-protein in-
teractions between cdc34 and Ub by using a stable covalent disulphide cdc34-
Ub to mimic the thiolester complex. Chemical shift mapping was used to iden-
tify sites of non-covalent interactions in the cdc34-Ub to create a model of the
complex. Competitive binding studies using free Ub or the cdc34 tail (residues
183-236) with cdc34-Ub indicate that transient non-covalent interactions exist
between cdc34 and Ub. These studies provide the first detailed structural infor-
mation to explain the unique mechanism used by cdc34 to promote poly-Ub
chain assembly.197-Pos
Binding of Small-Molecule Inhibitors ToMAPKinase ERK2, Studied with
Resonance Energy Transfer (RET)
Kerrick Nevels, Paul Shapiro, Peter Butko.
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The extracellular-signal-regulated kinase (ERK) proteins belong to the mito-
gen-activated protein kinase family. They participate in several important
cell-signaling pathways. Unregulated, ERK2 is thought to mediate cell prolif-
eration in many types of cancer. But because ERK also functions in many
normal cell activities, inhibition selectivity is necessary for its use in cancer
therapy: one needs to block only phosphorylation of those substrates that are
involved in cell proliferation, while leaving phosphorylation of other substrates
unaffected. Novel small-molecule compounds, which inhibit phosphorylation
of selected substrates but do not compete with ATP for its binding site, have
been previously identified by computer-aided drug design (CADD) and molec-
ular-dynamics docking algorithms. Herein, we spectroscopically characterized
selected compounds, and show that they can serve as resonance energy transfer
(RET) acceptors for tryptophan: we determined the values of spectral overlap J
between the compounds’ absorption and ERK fluorescence, and of the Forster
distance R0 for the compound/tryptophan pairs. We then used RET to deter-
mine average distances between the bound compounds and the group of three
tryptophans in ERK2, thus validating the CADD predictions of the compounds’
binding sites. The problem of multiple but closely located donors (tryptophans)
that pass the energy to the single acceptor (the bound compound) is discussed,
as is the possibility of utilizing RET for mapping the inhibitor-binding sites on
other kinases. The novel RET acceptors for tryptophan can conceivably be em-
ployed in studies of other protein/ligand systems with suitable spectroscopic
properties.198-Pos
Receptor Transactivation Measured in Live Cells Using Spatial Intensity
Distribution Analysis (spida)
Antoine G. Godin1, Jody L. Swift1, Kim Dore´1, Mikhail Sergeev1,
Laure Freland2, Yves De Koninck3, Martin J. Beaulieu3, Paul W. Wiseman1.
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Recent evidence suggests that signaling responses elicited by G-protein cou-
pled receptors (GPCRs) are more complex than first believed. For instance,
stimulation of several GPCRs leads to the transactivation of receptor tyrosine
kinase (RTK) signaling pathways. Many groups have studied the role and
mechanistic details of RTK-GPCR cross communication, using standard
biochemical methods. While these studies have helped to elucidate possible
intermediates involved in this complex network, the diversity of cell types and
receptors used has often lead to conflicting results and provided little quantita-
tive information.
We present a quantitative measurement of RTK transactivation, using spatial
intensity distribution analysis (SpIDA). Employing confocal microscopy, spa-
tial intensity histograms are fit using super-Poissonian distributions, yielding
molecular parameters such as density and particle quantal brightness. SpIDA
provides measurement of particle densities and oligomerization states of recep-
tors using single images as input. Thus processes such as transactivation, which
results in changes in the oligomerization state, can be monitored. CHO-K1 cells
expressing EGFR-GFP were transfected with various GPCRs including b2-ar-
restin, neurokinin1, angeotensin and dopamine receptors. We monitored the
relative distribution of monomeric and dimeric EGFR in response to GPCR
stimulation and obtained dose response curves for different EGFR-GFP:GPCR
interactions.
To confirm our findings, similar dose response curves were obtained using
FLIM-FRET data and negative controls were also measured when activation
or transactivation was blocked with a variety of biochemical agents including
Rab5 and AG1478.
By fitting dose response curves to standard models, key parameters such as D50,
and Dmax were obtained. To show that those results were not biased by either
cell type choice or overexpression, we studied transactivation in situ in primary
